Caris Life Sciences

Myeloid malignancies demand precision across diagnosis, risk stratification and treatment selection. Caris ChromoSeq leverages high-coverage Whole Genome Sequencing (WGS) to consolidate cytogenetics, FISH and targeted next-generation sequencing (NGS) into a single assay. One test. One integrated report. A more complete molecular picture. Simplify your workflow while supporting confident clinical decisions in complex myeloid cases. Learn more: https://bit.ly/4ufznZw

Are you confident a single test is sufficient for comprehensive molecular profiling in advanced disease? For some patients, combining tissue and whole blood (plasma + white blood cells) sequencing can improve detection of targetable variants, supporting more informed treatment planning. Learn why clinicians are incorporating Caris Assure® alongside MI Cancer Seek® to help achieve a more complete molecular picture. Learn more: https://ow.ly/J8CW50ZjHym

The NRG Oncology 2026 Summer Meeting brings together oncology professionals advancing cancer research. Visit Caris at Booth 4 to discover our latest innovations that deliver deeper molecular insight and help inform cancer treatment decisions. Learn more and schedule a meeting with our team: https://ow.ly/thtI50Zk6Zx

From all of us at Caris Life Sciences, we wish you and your family a happy and safe Independence Day. As we mark the 250th anniversary of the Declaration of Independence, we hope you enjoy a wonderful Fourth of July celebration.

Precision oncology requires tools that can adapt to real-world clinical challenges. Caris Assure® is a blood-based assay designed to provide comprehensive molecular insights for therapy selection in advanced solid tumors, particularly when tissue is limited or unavailable. By sequencing whole blood, Assure helps clinicians interpret results with greater confidence and clarity. Learn more: https://bit.ly/4eYqHQO

Sarcoma represents a diverse group of rare cancers that often require specialized expertise and advanced diagnostics. At Caris Life Sciences, we’re committed to helping physicians navigate these complex cases with comprehensive molecular profiling that supports informed, personalized treatment strategies. As we recognize Sarcoma Awareness Month, we stand with clinicians working to deliver clarity and options to patients facing these rare malignancies. Learn more about our molecular insights in sarcoma care: https://ow.ly/qiJ450ZibOF

Caris Life Sciences announced the commercial launch of Caris Detect™, a groundbreaking multi-cancer early detection blood test designed to uncover cancer signals at earlier, more treatable stages. Using ultra-deep Whole Genome Sequencing, Whole Transcriptome Sequencing and advanced AI, the test analyzes a broad spectrum of molecular and biological signals associated with cancer, offering a more comprehensive approach than technologies that rely on limited genomic snapshots. Learn more: https://ow.ly/mkGa50ZiVwj

MI Cancer Seek® is the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved CDx indications for molecular profiling of solid tumors. MI Cancer Seek is available for adult and pediatric patients. Get more product information here: https://bit.ly/4lyGNTR

A new approach to prognostic assessment in early-stage breast cancer: Caris MI Clarity™ is trained and validated on TAILORx and NSABP B-42 clinical trial data, delivering independent risk insights across 15 years from a single diagnostic sample. Review the clinical evidence: https://lnkd.in/gMjgJC9R

Liquid biopsy offers a non-invasive path to molecular insights, but how it’s generated can affect clinical clarity. Caris Assure® sequences whole blood, integrating plasma and white blood cell analysis to reduce biologic noise and improve interpretability. The result: more confident identification of actionable biomarkers to guide precision treatment decisions. Learn more: https://bit.ly/4eYqHQO